Anti-NME antibody and method of treating cancer or cancer metastasis
The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
1. A monoclonal antibody comprising:
an amino acid sequence in the heavy chain variable region comprising the following:
in the CDR1 region NTFTEYTMH (SEQ ID NO: 388);
in the CDR2 region GFNPNNGVTNYNQKFKG (SEQ ID NO: 389); and
in the CDR3 region RYYHSLYVFYFDY (SEQ ID NO: 390); and
an amino acid sequence in the light chain variable region comprising the following:
in the CDR1 region SASQGISNYLN (SEQ ID NO:393);
in the CDR2 region YTSSLHS (SEQ ID NO: 394); and
in the CDR3 region QQYSKLPYT (SEQ ID NO: 395).
2. The monoclonal antibody of claim 1 , comprising:
(a) an amino acid sequence in the heavy chain variable region comprising a sequence of SEQ ID NO: 1139; and
(b) an amino acid sequence in the light chain variable region comprising a sequence of SEQ ID NO: 1109.
3. The monoclonal antibody of claim 1 , comprising:
(a) an amino acid sequence in the heavy chain variable region comprising a sequence of any one of SEQ ID NOs: 1102, 1106, or 1133; and
(b) an amino acid sequence in the light chain variable region comprising a sequence of any one of SEQ ID NOs: 1104, 1108, or 1135.
4. The monoclonal antibody of claim 1 , which is monovalent.
5. The monoclonal antibody of claim 1 , which is an Fab or a single chain variable fragment antibody (scFv).
6. The monoclonal antibody of claim 1 , which is bispecific.
7. A bispecific T-cell engager comprising the monoclonal antibody of claim 1 .
8. The monoclonal antibody of claim 1 , which is humanized or an engineered antibody mimic.
9. An isolated nucleic acid encoding the monoclonal antibody of claim 1 .
10. A method of treating a MUC1*-dependent cancer comprising administering a pharmaceutical composition comprising the antibody of claim 1 .
11. The method of claim 10 , wherein the pharmaceutical composition inhibits cancer metastasis.
12. The method of claim 10 , wherein the pharmaceutical composition inhibits growth of cancer cells that express MUC1*.
13. A method for diagnosing cancer or cancer metastasis comprising contacting cells of an individual suspected of having cancer or a cancer metastasis with the monoclonal antibody of claim 1 .
14. The method of claim 13 , wherein the cells are cells of a tissue or tissue sample.
15. The method of claim 13 , wherein the cells are in vitro.
16. A cell comprising a nucleic acid encoding the monoclonal antibody of claim 1 .